Decriminalization of Diverted Buprenorphine in Burlington, Vermont and Philadelphia: An Intervention to Reduce Opioid Overdose Deaths.
作者信息
Pozo Brandon Del, Krasner Lawrence S, George Sarah F
机构信息
Brandon del Pozo, Ph.D., M.P.A., M.A., is a Postdoctoral Fellow, Miriam Hospital/Warren Alpert Medical School of Brown University, and Research Fellow, Global Law Enforcement and Public Health Association Lawrence S. Krasner, J.D., is the District Attorney of Philadelphia. Sarah F. George, J.D., is a a State's Attorney, Chittenden County, Vermont.
出版信息
J Law Med Ethics. 2020 Jun;48(2):373-375. doi: 10.1177/1073110520935353.
Abstract
摘要
相似文献
1
Decriminalization of Diverted Buprenorphine in Burlington, Vermont and Philadelphia: An Intervention to Reduce Opioid Overdose Deaths.
J Law Med Ethics. 2020 Jun;48(2):373-375. doi: 10.1177/1073110520935353.
2
Beliefs and Attitudes about Vermont's Buprenorphine Decriminalization Law among Clinicians Who Prescribe Buprenorphine.
Subst Use Misuse. 2024;59(1):150-153. doi: 10.1080/10826084.2023.2262014. Epub 2023 Dec 1.
3
Attitudes and beliefs about Vermont's 2021 buprenorphine decriminalization law among residents who use illicit opioids.
Drug Alcohol Depend. 2023 Sep 1;250:110879. doi: 10.1016/j.drugalcdep.2023.110879. Epub 2023 Jul 6.
4
CommunityStat: A Public Health Intervention to Reduce Opioid Overdose Deaths in Burlington, Vermont, 2017-2020.
Contemp Drug Probl. 2022 Mar;49(1):3-19. doi: 10.1177/00914509211052107. Epub 2021 Oct 6.
5
Commentary on Glanz et al.: Longer buprenorphine treatment duration is associated with lower rates of opioid overdose, but can we address barriers to staying in treatment?
Addiction. 2023 Jan;118(1):108-109. doi: 10.1111/add.16032. Epub 2022 Aug 31.
6
Vermont responds to its opioid crisis.
Prev Med. 2015 Nov;80:10-1. doi: 10.1016/j.ypmed.2015.04.002. Epub 2015 Apr 11.
7
Improve Access to Care for Opioid Use Disorder: A Call to Eliminate the X-Waiver Requirement Now.
Ann Emerg Med. 2021 Aug;78(2):220-222. doi: 10.1016/j.annemergmed.2021.03.023. Epub 2021 May 7.
8
Legal Authority for Emergency Medical Services to Increase Access to Buprenorphine Treatment for Opioid Use Disorder.
Ann Emerg Med. 2021 Jul;78(1):102-108. doi: 10.1016/j.annemergmed.2021.01.017. Epub 2021 Mar 27.
9
Injecting Opioid Use Disorder Treatment in Jails and Prisons: The Potential of Extended-release Buprenorphine in the Carceral Setting.
J Addict Med. 2022;16(4):396-398. doi: 10.1097/ADM.0000000000000942. Epub 2021 Dec 23.
10
A health crisis within a health crisis: Opioid access in the COVID-19 pandemic.
Subst Abus. 2021;42(2):148-152. doi: 10.1080/08897077.2021.1900981. Epub 2021 Apr 13.
引用本文的文献
1
Police Knowledge, Attitudes, and Beliefs About Opioid Addiction Treatment and Harm Reduction: A Survey of Illinois Officers.
J Drug Issues. 2025 Apr;55(2):239-259. doi: 10.1177/00220426231212567. Epub 2023 Nov 3.
2
"Either way, they will use. And so, probably, would you:" A critical discourse analysis of harm reduction portrayal in United States opinion news media.
Int J Drug Policy. 2025 Jun;140:104801. doi: 10.1016/j.drugpo.2025.104801. Epub 2025 Apr 11.
3
Beliefs of US chiefs of police about substance use disorder, fentanyl exposure, overdose response, and use of discretion: results from a national survey.
Health Justice. 2025 Mar 5;13(1):13. doi: 10.1186/s40352-025-00318-8.
4
Drug Decriminalization, Fentanyl, and Fatal Overdoses in Oregon.
JAMA Netw Open. 2024 Sep 3;7(9):e2431612. doi: 10.1001/jamanetworkopen.2024.31612.
5
Antecedents of fatal overdose in an adult cohort identified through administrative record linkage in Indiana, 2015-2022.
Drug Alcohol Depend. 2023 Jun 1;247:109891. doi: 10.1016/j.drugalcdep.2023.109891. Epub 2023 Apr 22.
6
Buprenorphine and opioid analgesics: Dispensation and discontinuity among accidental overdose fatalities in the Indianapolis metropolitan area, 2016-2021.
J Subst Use Addict Treat. 2023 Jul;150:209053. doi: 10.1016/j.josat.2023.209053. Epub 2023 Apr 25.
7
Scope of, Motivations for, and Outcomes Associated with Buprenorphine Diversion in the United States: A Scoping Review.
Subst Use Misuse. 2023;58(5):685-697. doi: 10.1080/10826084.2023.2177972. Epub 2023 Feb 20.
8
Buprenorphine involvement in opioid overdose deaths: A retrospective analysis of postmortem toxicology in Marion County, Indiana, 2015-2021.
Drug Alcohol Depend Rep. 2023 Mar;6. doi: 10.1016/j.dadr.2023.100131. Epub 2023 Jan 4.
9
Reducing the Iatrogenesis of Police Overdose Response: Time Is of the Essence.
Am J Public Health. 2022 Sep;112(9):1236-1238. doi: 10.2105/AJPH.2022.306987. Epub 2022 Jul 21.
10
CommunityStat: A Public Health Intervention to Reduce Opioid Overdose Deaths in Burlington, Vermont, 2017-2020.
Contemp Drug Probl. 2022 Mar;49(1):3-19. doi: 10.1177/00914509211052107. Epub 2021 Oct 6.
本文引用的文献
1
Demystifying buprenorphine misuse: Has fear of diversion gotten in the way of addressing the opioid crisis?
Subst Abus. 2019;40(2):148-153. doi: 10.1080/08897077.2019.1572052. Epub 2019 Apr 22.
2
Understanding the use of diverted buprenorphine.
Drug Alcohol Depend. 2018 Dec 1;193:117-123. doi: 10.1016/j.drugalcdep.2018.09.007. Epub 2018 Oct 12.
3
Suboxone: Rationale, Science, Misconceptions.
Ochsner J. 2018 Spring;18(1):23-29.
4
A qualitative study comparing physician-reported barriers to treating addiction using buprenorphine and extended-release naltrexone in U.S. office-based practices.
Int J Drug Policy. 2018 Apr;54:9-17. doi: 10.1016/j.drugpo.2017.11.021. Epub 2018 Jan 8.
5
Barriers to Medications for Addiction Treatment: How Stigma Kills.
Subst Use Misuse. 2018 Jan 28;53(2):330-333. doi: 10.1080/10826084.2017.1363238. Epub 2017 Sep 29.
6
Public health errors: costing lives, millions at a time.
J Public Health Manag Pract. 2010 May-Jun;16(3):211-5. doi: 10.1097/PHH.0b013e3181bee698.
Zotero 插件